Hodgkin's disease: clinical presentation and treatment.
Tirelli
U
U
Aviano Cancer Center.
Vaccher
E
E
Spina
M
M
Carbone
A
A
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001761:Bleomycin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D020031:Epstein-Barr Virus Infections / Q000150:complications; D005060:Europe; D015658:HIV Infections / Q000150:complications* / Q000453:epidemiology; D006689:Hodgkin Disease / Q000150:complications* / Q000453:epidemiology / Q000473:pathology; D018451:Homosexuality, Male; D006801:Humans; D015994:Incidence; D008198:Lymph Nodes / Q000473:pathology; D008297:Male; D008466:Mechlorethamine / Q000627:therapeutic use; D009894:Opportunistic Infections / Q000150:complications; D011241:Prednisone / Q000627:therapeutic use; D011344:Procarbazine / Q000627:therapeutic use; D011379:Prognosis; D016539:Reed-Sternberg Cells / Q000473:pathology; D014481:United States; D014747:Vinblastine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D001761:Bleomycin; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin; D011241:Prednisone